ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 67 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,626,206 | +25.3% | 180,768 | +76.1% | 0.00% | +33.3% |
| Q2 2023 | $2,895,136 | +103.5% | 102,628 | +24.1% | 0.00% | +50.0% |
| Q1 2023 | $1,422,560 | -14.6% | 82,707 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,665,719 | -6.3% | 82,707 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,777,000 | -23.4% | 82,707 | +0.1% | 0.00% | -33.3% |
| Q2 2022 | $2,321,000 | -52.5% | 82,607 | -22.0% | 0.00% | -25.0% |
| Q1 2022 | $4,886,000 | -50.6% | 105,903 | -10.0% | 0.00% | -50.0% |
| Q4 2021 | $9,888,000 | +62.6% | 117,633 | +28.9% | 0.01% | +33.3% |
| Q3 2021 | $6,081,000 | +39.4% | 91,258 | +11.3% | 0.01% | +50.0% |
| Q2 2021 | $4,361,000 | +243.9% | 81,966 | +180.6% | 0.00% | +300.0% |
| Q1 2021 | $1,268,000 | -0.3% | 29,215 | +19.3% | 0.00% | -50.0% |
| Q4 2020 | $1,272,000 | +73.1% | 24,493 | +8.9% | 0.00% | +100.0% |
| Q3 2020 | $735,000 | -31.9% | 22,493 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $1,080,000 | – | 22,493 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |